Trials of the controversial anti-malarial drug taken by US President Donald Trump to attempt to stop catching coronavirus are to be resumed.
UK regulators say hydroxychloroquine and an analogous drug chloroquine will be given to healthcare employees in a scientific examine to check the speculation.
Recruitment to the COPCOV trial had been paused amid considerations about side-effects raised by other research that has since been discredited.
That work checked out treating Covid-19.
It concluded the drug was not helpful and elevated the chance of irregular coronary heart rhythms and demise. That publication led to the WHO suspending its coronavirus remedy trials of the anti-malaria drug.
Considerations had been raised concerning the information after which a number of the examine’s authors stated they might no longer stand by their publication in The Lancet because the healthcare agency Surgisphere that was concerned within the work wouldn’t permit an unbiased evaluation.
The COPCOV trial will see chloroquine, hydroxychloroquine or a placebo given to greater than 40,000 healthcare employees from Europe, Africa, Asia and South America.
One of many lead researchers, Prof Sir Nicholas White from the College of Oxford, stated: “Hydroxychloroquine might nonetheless stop infections, and this must be decided in a randomised managed trial.”
Co-investigator Prof Martin Llewelyn, from the Brighton and Sussex Medical College, stated: “Though charges of coronavirus are low simply now within the UK, healthcare employees are nonetheless being affected throughout the NHS and a second wave of an infection this winter is extensively anticipated.
“By way of discovering an intervention that might defend key employees by this winter, hydroxychloroquine is by far essentially the most reasonable prospect. The current post-exposure prophylaxis examine confirmed its security and indicated that it may very well be protecting if given as pre-exposure prophylaxis. That is what COPCOV will discover out.”